The SEC and DOJ have expanded their investigations of Eli Lilly & Co.’s compliance with the Foreign Corrupt Practices Act. The Wall Street Journal reports that the investigation now includes Lilly’s activities in additional countries. The SEC began investigating Lilly in 2003 The SEC initially notified Lilly in 2003 that it was probing whether its Polish unit had violated the Foreign Corrupt Practices Act
Lilly filed a regulatory document on Monday stating that authorities have recently increased this type of enforcement against drug companies. According to the Wall Street Journal, enforcing the FCPA against drug companies can be difficult because many health systems are government-run. As a result, employees at drug companies who give items of value to doctors and health ministry officials of state-run health systems may violate the FCPA.